Business Context and Reporting Period
This Form 8-K filing by Imunon, Inc. (IMNN) is dated May 30, 2025. The report addresses a critical corporate governance event: the receipt of a delisting determination from The Nasdaq Stock Market LLC due to non-compliance with continued listing standards.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, cash flow, or debt figures. However, it discloses the following financial thresholds relevant to listing status:
- Minimum Bid Price: The company failed to maintain the required $1.00 per share closing bid price for 30 consecutive business days.
- Stockholders' Equity: The company failed to meet the minimum stockholders' equity requirement of $5,000,000 for the Nasdaq Capital Market.
- Liquidity Impact: Potential delisting could impair the company's ability to raise capital and affect the liquidity of its common stock.
Material Changes and Events
The primary material change is the formal determination of delisting by Nasdaq:
- Original Notice: Received on November 26, 2024, regarding failure to meet the $1.00 minimum bid price.
- Compliance Period: The 180-day compliance period expired on May 27, 2025, without the company regaining compliance.
- Additional Deficiency: On May 19, 2025, the company received a deficiency letter for failing to meet the $5,000,000 minimum stockholders' equity requirement.
- Delisting Determination: Received on May 28, 2025, stating that trading will be suspended and the stock delisted on June 6, 2025, unless an appeal is filed.
Outlook, Management Commentary, and Risks
Management intends to request a hearing before a Nasdaq Hearing Panel by June 4, 2025, to appeal the delisting determination. Key points include:
- Appeal Strategy: The company expects the hearing request to stay the suspension of trading pending the conclusion of the hearing process, which typically occurs 30-45 days after the request.
- Compliance Plan: The company plans to present a plan to regain compliance, which may include implementing a reverse stock split, subject to Board and stockholder approval.
- Risks: There is no assurance that the company will regain compliance, successfully implement a reverse split, or that the appeal will be successful. Delisting could lead to a material decline in stock price, reduced liquidity, and potential defaults on outstanding agreements.
Investor Verification Checklist
- Verify the filing of the hearing request with Nasdaq by the June 4, 2025 deadline.
- Monitor the status of the proposed reverse stock split and any required stockholder approvals.
- Review the company's most recent financial statements to confirm the current stockholders' equity balance relative to the $5,000,000 threshold.
- Check for any subsequent announcements regarding the scheduling of the Nasdaq Hearing Panel.
- Assess the potential impact of delisting on the company's ability to secure future financing.